This study focuses on the drug clozapine, which is used to treat people with schizophrenia who don't respond well to other treatments. While clozapine can be effective, it sometimes leads to serious side effects like neutropenia (low levels of a type of white blood cell called neutrophils) and agranulocytosis (an extremely low neutrophil count), which can make patients vulnerable to infections.
The researchers looked at 811 patients in the UK who were taking clozapine but hadn't developed neutropenia. They wanted to understand if the amount of clozapine in the blood and the patient's genetic makeup could influence their neutrophil count. They found that higher doses of clozapine were generally associated with higher neutrophil counts—about a 133-cell increase per each standard deviation increase in the dose of the drug.
The effect of clozapine on neutrophil count was partly due to the levels of clozapine and its byproduct, norclozapine, in the plasma, which had different impacts on the neutrophil count. Additionally, they discovered that a patient's genetic ability to metabolize clozapine, particularly through an enzyme called CYP1A2, also affected their neutrophil levels. People with a lower ability to metabolize clozapine (poor metabolizers) had lower neutrophil counts.
These findings could help doctors identify which patients are at higher risk of developing low neutrophil counts while using clozapine, allowing for better monitoring and prevention strategies to manage this side effect.